Clinical Trial Update: Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating subcutaneous alemtuzumab with oral dexamethasone followed by alemtuzumab maintenance or allo-SCT in CLL with 17p- or fludarabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• dexamethasone (oral) (dexamethasone)

Snippet

Sponsor: University of Ulm | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED